Number of the records: 1  

Nanodiamonds as an innovative system for intracellular delivery of mirna-34a inprostatic cancer therapy

  1. 1.
    SYSNO ASEP0499421
    Document TypeC - Proceedings Paper (int. conf.)
    R&D Document TypeConference Paper
    TitleNanodiamonds as an innovative system for intracellular delivery of mirna-34a inprostatic cancer therapy
    Author(s) Bitti, G. (IT)
    Abate, M. (IT)
    Neuhoferová, Eva (MBU-M) ORCID
    Kindermann, Marek (MBU-M)
    Petráková, V. (CZ)
    Boccellino, M. (IT)
    Quagliuolo, L. (IT)
    Filová, Eva (UEM-P) RID, ORCID
    Benson, Veronika (MBU-M) RID, ORCID
    Caraglia, M. (IT)
    Amler, Evžen (UEM-P) RID
    Source TitleNanodiamonds as an innovative system for intracellular delivery of mirna-34a inprostatic cancer therapy. - Ostrava : Tanger Ltd, 2018 - ISBN 978-80-87294-81-9
    Pagess. 449-454
    Number of pages6 s.
    Publication formPrint - P
    Action9th International Conference on Nanomaterials - Research and Application (NANOCON)
    Event date18.10.2017 - 20.10.2017
    VEvent locationBrno
    CountryCZ - Czech Republic
    Event typeWRD
    Languageeng - English
    CountryCZ - Czech Republic
    KeywordsmiR-34a ; nanodiamonds ; prostate cancer
    Subject RIVEE - Microbiology, Virology
    OECD categoryMicrobiology
    R&D ProjectsNV15-33094A GA MZd - Ministry of Health (MZ)
    Institutional supportMBU-M - RVO:61388971 ; UEM-P - RVO:68378041
    UT WOS000452823300073
    EID SCOPUS85052292166
    AnnotationThe microRNA(miRNA)-34a is an important regulator of tumor suppression. It controls the expression of several target proteins involved in cell cycle, differentiation and apoptosis, and antagonizes processes that are necessary for basic cancer cell viability as well as cancer stemness, metastasis, and chemoresistance. It is downregulated in numerous cancer types, including prostatic cancer, and inhibits malignant growth by repressing genes involved in various oncogenic signaling pathways. Given the anti-oncogenic activity of miR-34a, here we proved the substantial benefits of a new therapeutic concept based on nanotechnology delivery of miRNA mimics. In order to monitor the miRNA-34a replacement, we used a fluorescent nanodiamond particles (FND) system with linked miRNA-34a mimic, which was delivered to PC3 and DU145 prostatic cancer cell lines. We used functionalized nanodiamonds coated with polyethylenimine to transfer miRNA-34a into PC3 and DU145 prostatic cancer cell lines and we measured the zeta-potential of these complexes before using them for in vitro experiments. A replacement of miRNA-34 was observed by monitoring levels of miRNA-34 via real-time PCR. Moreover, our in vitro experiments demonstrated that miRNA-34a replacement, using this FND delivery system, decreased viability and induced apoptosis in prostatic cancer cell lines. Our findings suggest the replacement of oncosuppressor miRNA-34a provides an effective strategy for cancer therapy and the FND-based delivery systems seems to be an excellent strategy for a safe and effective targeting of the tumor.
    WorkplaceInstitute of Microbiology
    ContactEliška Spurná, eliska.spurna@biomed.cas.cz, Tel.: 241 062 231
    Year of Publishing2019
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.